{"id":130478,"date":"2022-06-06T12:17:07","date_gmt":"2022-06-06T16:17:07","guid":{"rendered":"https:\/\/44.250.171.167\/?p=130478"},"modified":"2022-10-06T04:26:42","modified_gmt":"2022-10-06T08:26:42","slug":"aurobindo-pharma-q4-fy-2022-research-tear-sheet","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q4-fy-2022-research-tear-sheet\/","title":{"rendered":"Aurobindo Pharma Q4 FY 2022 Research Tear Sheet"},"content":{"rendered":"\n

Aurobindo Pharma Limited is an Indian pharmaceutical company. It was established in the year 1986. The founders include Mr. P.V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals. The company started its operation in the year 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry.
The company is mainly focused on R&D and innovation. Aurobindo Pharma ranks second in India in Pharmaceutical Industry. 90% of revenues derived by Arobindo Pharma are from international operations. The company has exported business in 150+countries. It mainly deals with generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses and animal health. The vision of the company is \u201cto become a leading and an admired global pharma company, ranked in the top 25 by 2030\u201d.
Country of operation<\/strong>
The company is headquartered in HITEC City, Hyderabad, India. It has expanded its generic drug market in new territories like Poland, Italy, Spain, Czech Republic, Portugal and France.
Product Portfolio
The company has its presence in key therapeutic segments which includes neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins.
Company Strategies<\/strong>
The company focuses on R&D. It has 5 R&D centres spread over 16000 square meters. It has 3 R&D centres in USA with 1700+ scientists & analysts. It has world class talent and it has launched multiple affordable products across multiple Therapeutic areas.
Key Financial Highlights
<\/p>\n\n\n\n

Amount (INR Cr)<\/td>Q4FY22<\/td>Q4FY21<\/td>Change YoY<\/td><\/tr>
Revenue from operations<\/td>5,809.40<\/td>6,007.10<\/td>-3.3<\/td><\/tr>
EBITDA before Forex and Other income<\/td>974.4<\/td>1,276.30<\/td>-23.7<\/td><\/tr>
PBT before JV, Forex and Exceptional items<\/td>740.8<\/td>1,055.70<\/td>-29.8<\/td><\/tr>
Net Profit<\/td>576.1<\/td>802<\/td>-28.2<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Financial Snapshots<\/strong>
Revenue from Operations decreased by 3.3% to at 5,809.4 Crores. The EBIDTA before Forex and Other income stood at INR 974.4 Cr and the margin for the quarter is 16.8 %. Net profit has declined to 576.1 crore from 802 crore compared to prior the quarter. Research & Development (R&D) spend in FY 22 is Rs 1,581 which is 6.7% of revenue. In Q4 FY 2022 Basic & Diluted EPS is Rs 9.84 per share.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Analysis of Revenue on basis of segment<\/strong><\/p>\n\n\n\n

For US formulation the revenue shows a decline of 1% YoY to INR 11,122.1 Crores. In Q4 the revenue shows a decline 4.7% y-o-y. In Europe the revenue grew by 6.9% YoY to INR 6,480.3 Crores. However, Q4 FY 2022 was relatively flat at INR 1,540.7 Crores. ARV business revenue shows a decline of 55.3% YoY to to INR 1,862.8 Crores. However, in Q4, business revenue declined 52% YoY to INR 235.9 Crores. For Growth market revenue grew 4.6% YoY to INR 1,503.9 Crores on the other hand, Q4 posted a growth of 28% Y-O-Y. The Active Pharmaceutical Ingredients posted revenue of INR 3,515.6 Crores with a growth of 13.9% YoY.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Regulatory Approvals<\/strong>
Aurobindo Pharma has filed 14 ANDAs including 3 Injectables with USFDA in Q4 FY22. However, it has received final approval for 3 ANDAs including 2 injectable products. For FY 2022 the company filed 727 ANDAs with USFDA and received approval for 505 ANDAs and 33 are still tentative. The final approval of ANDA includes Colchicine Tablets, USP used as an Anti-Inflammatory Agent, Doxercalciferol Injection used as an Anti-Parathyroid Agent and Esmolol Hydrochloride in Sodium Chloride Injection (gBrevibloc) mainly used as a Cardio Vascular Drugs.
Operational Efficiency<\/strong>
Aurobindo Pharma has moved with phase 1 clinical trial with immunology assets and expects that it will be in the top three products by 2024-25 with a $4 billion potential market opportunity. Most of the clinical trials are in the review procedure, however the company anticipates that if everything goes well then Q1 2023 would be a potential launch into the Indian market.<\/p>\n","protected":false},"excerpt":{"rendered":"

Aurobindo Pharma Limited is an Indian pharmaceutical company. It was established in the year 1986. The founders include Mr. P.V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals. The company started its operation in the year 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry.The company is […]<\/p>\n","protected":false},"author":1796,"featured_media":58681,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[6352,9908],"tags":[9138,1115],"class_list":["post-130478","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-summary","category-research-tear-sheet","tag-pharma","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":133199,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q1-fy-2023-research-tear-sheet\/","url_meta":{"origin":130478,"position":0},"title":"Aurobindo Pharma Limited Q1 FY 2023 Research Tear Sheet","author":"sreerupa","date":"August 15, 2022","format":false,"excerpt":"Stock Data Ticker: AUROPHARMA Exchange :NSE and BSE Industry: Automobile Price Performance Last 7 days\u00a0\u00a0\u00a0 4.36% YTD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 -19.19% Last 12 months\u00a0\u00a0\u00a0\u00a0 -28.17% It will be beneficial to invest in the stocks of Aurobindo Pharma. The company enjoys a \u00a0healthy\u00a0ROE of\u00a021.49% ROE which is an\u00a0 important financial parameter. The company has\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":128324,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q3-fy-2022-research-tear-sheet\/","url_meta":{"origin":130478,"position":1},"title":"Aurobindo Pharma Q3 FY 2022 Research Tear Sheet","author":"sreerupa","date":"March 23, 2022","format":false,"excerpt":"Aurobindo Pharma Limited\u00a0is an Indian\u00a0pharmaceutical company. It is based in \u00a0HITEC City,\u00a0Hyderabad, India. It was incorporated in 1986. The pharmaceutical products include generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses and animal health. The company markets its products in more 125+ countries by Pfizer and AstraZeneca plc. The shares are\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":142550,"url":"https:\/\/alphastreet.com\/india\/earnings-aurobindo-pharma-ltd-nseauropharma-q3fy23-results-out-total-income-rise-7-yoy\/","url_meta":{"origin":130478,"position":2},"title":"Earnings | Aurobindo Pharma Ltd. (NSE:AUROPHARMA): Q3FY23 Results Out; Total Income rise 7% YoY","author":"Divyansh_Kasana","date":"February 22, 2023","format":false,"excerpt":"Aurobindo Pharma Ltd. (NSE:AUROPHARMA) is a global pharmaceutical company headquartered in India. The company produces and sells a wide range of generic pharmaceutical products and active pharmaceutical ingredients (APIs) in over 150 countries. Aurobindo Pharma's portfolio includes antibiotics, anti-retrovirals, anti-inflammatory drugs, cardiovascular drugs, and more. The company operates manufacturing facilities\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":140759,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-nse-auropharma-q3-fy23-results-out-total-income-rises-7-yoy\/","url_meta":{"origin":130478,"position":3},"title":"Aurobindo Pharma Limited (NSE: AUROPHARMA): Q3 FY23 Results Out; Total Income Rises 7% YoY","author":"Divyansh_Kasana","date":"February 9, 2023","format":false,"excerpt":"Aurobindo Pharma Limited (NSE: AUROPHARMA) is a pharmaceutical company based in Hyderabad, India. The company was founded in 1986 and has since grown to become one of the largest pharmaceutical companies in India, with a presence in over 150 countries. Aurobindo Pharma produces a wide range of generic and specialty\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":148570,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-driving-growth-in-the-pharmaceutical-industry\/","url_meta":{"origin":130478,"position":4},"title":"Aurobindo Pharma: Driving Growth in the Pharmaceutical Industry","author":"Divyansh_Kasana","date":"June 8, 2023","format":false,"excerpt":"Stock Data: TickerNSE: AUROPHARMAExchangeNSEIndustryPHARMACEUTICALS Price Performance: Last 5 Days+2.46%YTD+54.04%Last 12 Months+26.40% Company Description: Aurobindo, a company based in Hyderabad since 1986, focuses on producing generic formulations and APIs. Most of Aurobindo's sales, around 90%, come from international markets. In the United States, the company is recognized as the fifth largest\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":147899,"url":"https:\/\/alphastreet.com\/india\/alphagraph-aurobindo-pharma-ltd-nse-auropharma-q4fy23-results-out-total-income-rises-13-yoy\/","url_meta":{"origin":130478,"position":5},"title":"Alphagraph | Aurobindo Pharma Ltd (NSE: AUROPHARMA): Q4FY23 Results Out; Total Income rises 13% YoY.","author":"Divyansh_Kasana","date":"May 31, 2023","format":false,"excerpt":"Aurobindo Pharma is a leading pharmaceutical company primarily involved in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company specializes in the production of APIs, which are the key components of pharmaceutical formulations. Aurobindo Pharma also focuses on the development, manufacturing, and distribution\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1796"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=130478"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130478\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/58681"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=130478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=130478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=130478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}